Celgene

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Reuters
Tue, 10/1/24 - 09:59 am
Bristol Myers Squibb
Celgene
Breyanzi
legal
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Reuters
Thu, 09/7/23 - 10:57 pm
Bristol Myers Squibb
Celgene
patents
legal
Pomalyst
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Fierce Pharma
Thu, 08/3/23 - 11:22 am
Bristol Myers Squibb
BeiGene
Celgene
BMS re-ups 'highly productive' legacy neurodegeneration partnership with Evotec for $50M upfront
Fierce Biotech
Tue, 03/28/23 - 10:44 pm
Bristol Myers Squibb
Celgene
Evotec
neurodegenerative disease
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Thu, 03/2/23 - 10:45 pm
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says
Fierce Pharma
Wed, 11/23/22 - 07:33 am
Bristol Myers Squibb
Celgene
Revlimid
patents
generics
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
Endpoints
Mon, 06/27/22 - 07:02 pm
Celgene
Bristol Myers Squibb
Breyanzi
legal
Bristol Myers dusts off an old Celgene chemotherapy for use in children with a rare blood cancer
Endpoints
Mon, 05/23/22 - 06:51 pm
Bristol Myers Squibb
Celgene
chemotherapy
FDA
Vidaza
MDS
Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan
Fierce Pharma
Tue, 12/14/21 - 10:43 am
Bristol Myers Squibb
Celgene
M&A
stock buybacks
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Endpoints
Tue, 08/17/21 - 10:56 pm
Bristol Myers Squibb
Celgene
Nimbus Therapeutics
psoriasis
deucravacitinib
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near
Fierce Pharma
Tue, 06/22/21 - 10:49 pm
Bristol Myers Squibb
Celgene
Revlimid
generics
Sun Pharma
patents
Bristol-Myers is sued for $6.4 billion over delayed cancer drug
Reuters
Thu, 06/3/21 - 11:14 pm
Bristol Myers Squibb
Breyanzi
legal
Celgene
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
Endpoints
Wed, 05/19/21 - 10:33 am
Bristol Myers Squibb
Exscientia
R&D
Celgene
M&A
artificial intelligence
Bristol’s buy moves it to the top of the sales charts
EP Vantage
Tue, 05/18/21 - 10:53 am
Celgene
Bristol-Myers Squibb
M&A
sales reps
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
Motley Fool
Thu, 02/4/21 - 08:07 pm
Bristol-Myers Squibb
Celgene
earnings
M&A
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Endpoints
Wed, 02/3/21 - 10:55 am
Bristol-Myers Squibb
Celgene
FDA
ulcerative colitis
priority review
Zeposia
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Fri, 01/29/21 - 09:57 am
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
BMS/Celgene merger payout evaporates as CVR deadline passes
Pharmaforum
Mon, 01/4/21 - 10:21 am
Celgene
Bristol-Myers Squibb
FDA
CVRs
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Tue, 12/8/20 - 10:41 am
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Endpoints
Mon, 11/16/20 - 10:43 pm
Bristol-Myers Squibb
CVRs
Celgene
M&A

Pages